

QIAGEN Spotlight Session – QuantiFERON (1/2)



Thierry Bernard
Chief Executive Officer

Thierry Bernard joined QIAGEN in February 2015 to lead our growing presence in molecular diagnostics, which involves the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis and became a member of the Managing Board in 2021.

Before joining QIAGEN, Mr. Bernard spent 15 years at bioMérieux SA in roles of increasing responsibility, most recently serving as Corporate Vice President for Global Commercial Operations, Investor Relations and the Greater China Region. Earlier in his career, he held senior management positions at several other leading international companies. He is also a member of the Board of Directors of Neogen Corporation and Bruker Corporation, and previously served as Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association.

Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona and has been appointed Conseiller du Commerce Extérieur by the French government.



Nitin Sood
Senior Vice President
Head of Product Portfolio & Innovation

Nitin Sood joined QIAGEN in 2023 as Senior Vice President, Head of the Life Sciences Business Area, and member of the Executive Committee, and was named Head of Product Portfolio & Innovation in January 2025.

He most recently served as Chief Commercial Officer, MRD, at Adaptive Biotechnologies. He has enjoyed a 20-year career in the diagnostic and life science fields, having also held leadership roles at Guardant Health, PerkinElmer, Agilent Technologies and NuGEN Technologies.

He holds a Master's degree from Delhi University in Molecular Biology and a Master's degree from Ball State University in Computer Science.

QIAGEN Spotlight Session – QuantiFERON (2/2)



Nadia Aelbrecht

Vice President
Head of Infectious Disease

Nadia Aelbrecht is Vice President of Infectious Diseases at QIAGEN, where she leads the strategic direction and growth of the company's global infectious diseases portfolio.

She joined QIAGEN in 2022 as Vice President of Syndromic Testing, bringing extensive experience from over three decades in diagnostics with focus on molecular syndromic testing and microbiology. Prior to QIAGEN, Nadia held senior leadership roles with increasing responsibility at Roche Diagnostics and bioMérieux.

Ms. Aelbrecht holds a Bachelor's degree from Vives and has successfully completed advanced training in marketing and global business leadership at IMD Lausanne and Duke University.



Parampal Deol

Head of R&D Applications,
QuantiFERON

Parampal Deol is Head of R&D Applications, QuantiFERON at QIAGEN, where she leads innovation and R&D initiatives for QuantiFERON within the Infectious Disease portfolio.

She joined QIAGEN in 2025, bringing more than 20 years of global diagnostics experience spanning microbiology, tuberculosis, pharma applications and immunoassays. Prior to joining QIAGEN, Ms. Deol held senior R&D and Operations leadership roles at bioMérieux, Accelerate Diagnostics and Charles River Laboratories, where she successfully launched multiple IVD and GMP-compliant products at global scale in highly regulated environments.

She holds a Doctorate from PGIMER, India and an MBA in Innovation and Marketing from NC State, NC. She has completed executive leadership programs at Duke University and Harvard University, including an executive program on AI from strategy to implementation and has also completed executive education at CEDEP, France.